Redx to present at ASM Microbe 2016 Conference

RNS Number : 5713B

Redx Pharma plc

17 June 2016

 

17 June 2016

AIM: REDX

 REDX PHARMA PLC

("Redx" or "the Company")

Redx to present Preclinical Data on Novel Bacterial Topoisomerase Inhibitors at ASM Microbe 2016 Conference

Redx, the drug discovery and development company, is pleased to announce that it will present data on its novel bacterial topoisomerase inhibitors ("NBTIs") at the inaugural annual American Society for Microbiology ("ASM") Microbe 2016 conference taking place from 16-20 June in Boston, Massachusetts.

Both the rise of antimicrobial resistance and the current antibiotic innovation gap have highlighted the need for novel antimicrobial agents, particularly for the treatment of Gram-negative bacterial infections. Redx is making promising progress in meeting this need following its discovery of a series of NBTIs that demonstrate broad-spectrum antibacterial activity against ESKAPE pathogens and low potential for resistance development.

Redx will be presenting the in vitro biological properties of its NBTIs, including activity against multi-drug resistant strains, preliminary assessment of safety profile and data on the in vivo exposure level of representative compounds.

No price-sensitive information will be provided during the presentation. A poster containing the relevant information will be made available on the Redx website following the presentation.

Details of the presentation are as follows:

Title: In Vitro Biology and Pharmacokinetics Evaluation of Novel Bacterial Topoisomerase Inhibitors

Session: 306: Fluoroquinolones and Other Topoisomerase (Therapeutics and Prevention Track)

Date: 19 June 2016

Time: 12:30-14:30 EST

Poster Location: BCEC, Exhibit and Poster Hall, Halls A and B

Poster Number: SU-463

For further information, please contact:

Redx Pharma Plc	T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
Cantor Fitzgerald Europe (Nomad & Broker)	T: 020 7894 7000
Phil Davies / Michael Reynolds
KTZ Communications	T: 020 3178 6378
Katie Tzouliadis/ Viktoria Langley/ Emma Pearson

About Redx Pharma Plc

www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Seven proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

 

END

 

 

NRAUBRARNRANAAR